

# TAYSIDE PRESCRIBER

## Tayside DTC Supplement No 88

April 2009

Produced by NHS Tayside Drug and Therapeutics Committee Medicines Advisory Group (MAG)

### SMC Advice issued in April 2009

Medicine	Indication	Local recommendation category	Comments and useful links
Brinzolamide 10mg/ml eye drops (Azopt®) - <i>abbreviated submission</i>	Monotherapy to decrease intraocular pressure in ocular hypertension and open angle glaucoma in patients unresponsive to beta-blockers or in whom beta-blockers are contraindicated. Adjunctive therapy to beta-blockers or prostaglandin analogues.	Non-formulary	<a href="#">SMC advice</a>
Budesonide CFC-free inhaler 100 micrograms and 200 micrograms (Pulmicort®) - <i>abbreviated submission (deferred)</i>	Treatment of asthma	Formulary	<a href="#">SMC advice</a> <a href="#">Link to SPC</a> Pulmicort CFC-free inhaler is not recommended in children less than 2 years of age
Cetuximab, 100mg/20ml and 500mg/100ml solution for intravenous infusion (Erbix®)	Treatment of metastatic colorectal cancer in combination with chemotherapy	<b>Not recommended</b>	<a href="#">SMC advice</a>
Fluticasone furoate 27.5 micrograms/actuation nasal spray (Avamys®)	Treatment of the symptoms of allergic rhinitis in adults, adolescents and children	Non-formulary	<a href="#">SMC advice</a> <ul style="list-style-type: none"> <li>Recommended doses of fluticasone furoate are not equivalent to other fluticasone nasal sprays currently available</li> <li>Current first line formulary choice for nasal allergy is beclometasone</li> </ul> <a href="#">Link to Section 12.2 TAPG</a>
Micronised progesterone 100mg, 200mg capsules (Utrogestan®)	Adjunctive use with oestrogen in post – menopausal women with an intact uterus (HRT)	<b>Not recommended</b>	<a href="#">SMC advice</a>
Topotecan 0.25mg, 1mg hard capsules (Hycamtin®)	Treatment of adults with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first line regimen is not considered appropriate	Pending OHMMG decision	<a href="#">SMC advice</a> <a href="#">Link to SPC</a>

Click here for [April](#) briefing note

## Sunitinib for first line treatment of advanced and/or metastatic renal cell carcinoma

NHS Quality Improvement Scotland has considered NICE ([Multiple Technology Appraisal Guidance no 169](#)) and advises that the recommendations are valid for NHS Scotland.

### Local recommendation

Sunitinib is approved for use in renal cell carcinoma in NHS Tayside in accordance with this guidance. The Policy for renal cell carcinoma will be changed in the light of this development.

## TAPG\* Update

	TAPG section	Drug(s)/topic	Changes
4.7	Analgesics	Soluble analgesics	Paracetamol 500mg soluble tablets and co-codamol 30/500 effervescent tablets removed from the formulary. Prescribing note added on sodium content of these preparations. Maximum dose of 8 tablets a day may exceed the maximum recommended daily amount (approximately 100 mmol of sodium)

### \* Please note:

The Tayside Area Prescribing Guide (T.A.P.G) can now be accessed from the home page of the Staffnet via the tool bar at the top - T.A.P.G. (3rd entry)

### [Forthcoming SMC Advice](#)

Local implementation of SMC recommendations is taken forward by the Tayside Medicines Governance Unit This bulletin is based on evidence available to the Tayside Medicines Governance Unit at time of publication and is covered by the Disclaimer and Terms & Conditions of use and access the [NHS Tayside Drug and Therapeutics Committee website](#)